Protocol Ledger

NCT04369469 · Phase III · TERMINATED

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

Interventional Phase III clinical trial protocol NCT04369469 sponsored by AstraZeneca in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-10 Enrollment: 202 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04369469
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)202 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04369469
Protocol FieldVerified Registry Value
NCT IdentifierNCT04369469
Consolidated Lead SponsorAstraZeneca
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment202 participants (ACTUAL)
Registered Start Date2020-05-10
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI